•  
  •  
  •  
  •  

2025-10-05 23:39:29

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth

Keywords Selected:  JubilantPharmova

Stock Report

  • Jubilant Pharmova announces Completion of Pharmacovigilance Inspection by the USFDA with No Observations
  • Jubilant Pharmova Ltd consolidated Q1 FY2025-26 profit slides to Rs. 102.9 crores
  • Jubilant Pharmova Limited recommends final dividend of Rs. 5
  • Jubilant Pharmova Ltd Q4 FY2024-25 consolidated PAT climbs to Rs. 153.6 crores
  • Jubilant Cadista Pharmaceuticals Inc., USA's facility receives EIR from USFDA
  • Jubilant Cadista Pharmaceuticals Inc receives 5 observations from USFDA for Salisbury facility
  • USFDA Inspection at Jubilant HollisterStier General Partnership's Contract manufacturing facility at Montreal, Canada
  • Jubilant Pharmova announces completion of USFDA audit of facility Located at Spokane, Washington, USA
  • USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
  • Jubilant Pharmova Ltd consolidated Q1 FY25 PAT surges to Rs. 482.1 crores
  • Jubilant Pharmova Ltd completes voluntary prepayment of USD 75 million term loan, equivalent to Rs. 626 Cr
  • Jubilant Pharmova announces completion of USFDA audit of contract manufacturing facility at Montreal, Canada
  • Jubilant's Radiopharma Business Announces Investment to Expand Positron Emission Tomography Radiopharmacy Network
  • Jubilant Pharmova Ltd announces voluntary prepayment of USD 75 million term loan, equivalent to Rs. 626 Cr
  • Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal, Canada
  • USFDA determines inspection classification of 'Voluntary Action Indicated' for the Solid dosage manufacturing facility at Roorkee, India
  • Jubilant Pharmova's wholly owned subsidiary to sell its entire 25.8% stake in Sofie Biosciences Inc., USA
  • Jubilant Pharmova Ltd reports consolidated Q1FY24 profit of Rs. 6.4 crores
  • Jubilant Pharmova Ltd Q4FY23 consolidated loss widens to Rs. 97.84 crores
  • Jubilant announces additional loan facility by Government of Canada for the Expansion of its CMO Montreal facility
  • USFDA assigns VAI classification to Jubilant Pharmova's API facility at Nanjangud
  • Jubilant Pharmova Ltd Q3 FY2023 consolidated loss at Rs. 15.67 crores
  • Jubilant's Radiopharma business receives NDA approval for Technetium Mertiatide Injection
  • USFDA completes inspection of Jubilant Pharmova's API Manufacturing Facility at Nanjangud, India

Latest Post

  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024